Posted on

Seelos Therapeutics Announces Senior Management Appointments

Seelos Therapeutics Announces Senior Management Appointments

NEW YORK, Sept. 1, 2021 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the promotions of Michael Golembiewski to Chief Financial Officer and Anthony Marciano to Chief Communications Officer, each effective September 1, 2021.

“I congratulate Michael and Anthony on their promotions, which are a testament to their abilities, hard work and dedication to Seelos,” said Raj Mehra Ph.D., Chairman and CEO of Seelos.

Mr. Golembiewski joined Seelos in January 2019 as Vice President, Finance. Previously, he was Vice President of Finance at Agile Therapeutics, Inc., a pre-commercial biotechnology company. He was also Vice President of Finance, Principal Accounting Officer and Corporate Controller at Pernix Therapeutics Holdings, Inc., a global commercial life sciences company. He was also Executive Director, Corporate Controller at NPS Pharmaceuticals, Inc., a global commercial life sciences company that was sold to Shire plc in 2015 for $5.2 billion. Mr. Golembiewski began his career in the biotechnology field with ImClone Systems Incorporated. He is a Certified Public Accountant (not in public practice) and obtained his Bachelor of Science degree in accounting from Rider University.

Mr. Marciano began his work with Seelos as a consultant in August 2017 and was appointed Head of Corporate Communications in January 2019. His role at Seelos will continue to be spearheading investor and media relations, introductions to advocacy groups, investment bank interactions and general corporate communications strategies. Mr. Marciano began as a healthcare-dedicated institutional equity salesman at Leerink, Swann and Company (currently Leerink Partners, LLC) in 2000 and immediately prior to Seelos served as a Senior Vice President at Jefferies. He has extensive experience interacting with the hedge fund and mutual fund communities and deep knowledge of the investment banking process including the structuring and placement of equity and debt transactions. Mr. Marciano holds a Bachelor of Science degree in Finance and Marketing from Manhattan College and a Master of Business Administration from the O’Malley School of Business at Manhattan College.   

Also, during the month of August, several Seelos employees, including certain members of senior management, purchased shares of Seelos stock in the open market.

About Seelos Therapeutics:

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company’s robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD),  Amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson’s Disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Forward Looking Statements

Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All information in this press release is as of September 1, 2021 and we undertake no duty to update this information. A more complete description of these risks can be found in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year-ended December 31, 2020 and our Quarterly Report on Form 10-Q for the quarter-ended June 30, 2021.

Contact Information:

Anthony Marciano
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com 
https://seelostherapeutics.com/ 
https://twitter.com/seelostx 
https://www.linkedin.com/company/seelos 

SOURCE Seelos Therapeutics, Inc.

Related Links

https://seelostherapeutics.com/

Posted on

Tryp Therapeutics to Present at H.C. Wainwright Global Investment Conference

Tryp Therapeutics to Present at H.C. Wainwright Global Investment Conference

SAN DIEGO – Sept. 1, 2021 – Tryp Therapeutics (CSE:TRYP; OTCQB:TRYPF) (“Tryp”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

The conference will be held virtually on September 13-15, 2021. Greg McKee, Chairman and CEO of Tryp, will provide an overview of the business and its pipeline including Tryp’s Psilocybin-For-Neuropsychiatric Disorders (PFNTM) program for chronic pain and other indications.

Registration for the conference can be accessed here. Tryp’s presentation will be available on-demand beginning September 13, 2021 at 7:00 a.m. EDT.

Tryp also announces that it has granted an aggregate of 1,200,000 stock options (the “Options”) to two members of its Board of Directors. The Options have an exercise price of $0.75 per share, are exercisable until August 31, 2031 (subject to vesting restrictions), and will be governed in accordance with the terms of the Company’s stock option plan.

About Tryp Therapeutics

Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-For-Neuropsychiatric Disorders (PFN™) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and other indications. The Company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and overeating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information, please visit www.tryptherapeutics.com.

Investor Inquiries:

Joe Green
Edison Group
investors@tryptherapeutics.com

Media Inquiries:

Joy Willis
Tryp Therapeutics
media@tryptherapeutics.com
1-833-811-8797

 

Forward-Looking Information

Certain information in this news release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans,” “targets,” “expects” or “does not expect,” “is expected,” “an opportunity exists,” “is positioned,” “estimates,” “intends,” “assumes,” “anticipates” or “does not anticipate” or “believes,” or variations of such words and phrases or state that certain actions, events or results “may,” “could,” “would,” “might,” “will” or “will be taken,” “occur” or “be achieved.” In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of Tryp’s final prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

DEA supports psychedelic medicine?

DEA Proposes Massive Increase In Marijuana And Psilocybin Production For Research To Develop FDA-Approved Medicines

The Drug Enforcement Administration (DEA) is working to accelerate the development of federally-approved psychedelic medicines!

The agency proposed a huge increase in the production of psilocybin, psilocin, and marijuana with the goal of advancing research and drug development.

The proposed production quotas have increased to 1,500 g for psilocybin and 1,000 g for psilocin – up 2,900% and 1,900% respectively from the initial 50 g quota.

 

Posted on

Largest import of shrooms

Red Light Holland Successfully Completes Canada’s Largest Legal Sale and Import of Psilocybe Truffles into Canada Under a Health Canada Approved Psilocybin Import Permit

Red Light Holland (TRUFF) successfully completed the largest legal import of psilocybin into Canada.

The company grew 1.5 kg of psilocybin truffles in the Netherlands and exported them to its lab partner in Montreal, CCrest Laboratories Inc., where they will be evaluated for active pharmaceutical ingredients (APIs).

The sale, which was approved under a Health Canada import permit, was the company’s second import of truffles into Canada and included three different strains of truffles.

Posted on

Blackhawk Growth to Complete Investment in Psychedelic and Wellness Company MindBio Therapeutics Pty Ltd.

Blackhawk Growth to Complete Investment in Psychedelic and Wellness Company MindBio Therapeutics Pty Ltd.

Vancouver, British Columbia – TheNewswire – August 31, 2021 – Blackhawk Growth Corp. (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Corporation” or “Blackhawk”), is pleased to announce that it has entered into a share purchase agreement, dated effective August 30, 2021, in which it will acquire control of MindBio Therapeutics Pty Ltd (“MindBio Therapeutics”).

MindBio Therapeutics is an arms-length privately held clinical stage drug development company that is pioneering psychedelic micro-dosing research and is advancing emerging therapies to treat a range of debilitating health conditions such as depression, anxiety, chronic pain, cognitive impairment and PTSD.

In a world’s first clinical trial of its kind, MindBio Therapeutics has started Phase 1 clinical trials at the University of Auckland in New Zealand, in a safety study of 80 participants micro-dosing LSD to patients. The study has received regulatory approval and government funding for the importing of LSD, laboratory work using the drug and approvals for participants to be prescribed the drug and then patients take the drug at home as they would any other medication. Approvals have also been received for Phase 2 clinical trials involving micro-dosing LSD in late-stage cancer patients experiencing end of life distress.

MindBio Therapeutics is also pioneering the development of micro-dose formulations and a range of technology and artificial intelligence applications to ensure the safe dosage, use and administration of psychedelic medicines in the community. Early indications show that LSD is tolerated well in micro-doses and has a lower side effect profile than the currently prescribed anti-depressant drugs.

MindBio Therapeutics completed an equity financing for proceeds of approximately AUD$1,300,000, which gives it sufficient working capital to complete Phase 1 clinical trials. Completion of this financing was critical for Blackhawk to ensure MindBio Therapeutics was properly capitalized prior to the acquisition.

“We are excited to become part of the Blackhawk portfolio, which expands our investor reach to the capital markets in North America and we are now truly a global company with connections in Australia, New Zealand and Canada. We are excited by the prospect of accelerating our clinical research micro-dosing psychedelic medicines in Phase 2 clinical trials and the next steps towards commercialisation” says Justin Hanka, Director of MindBio Therapeutics.

“The acquisition of MindBio Therapeutics will help to scale our life science and psychedelic portfolio” said Frederick Pels, CEO of Blackhawk. “Complementing our current assets, a clinical trial and a management team with decades of experience in the health sector will enable Blackhawk and MindBio Therapeutics to be leaders in the legal psychedelic treatment industry that we believe will only continue to grow exponentially. We look forward to updating our shareholders with our progress over the coming months.”

MindBio Therapeutics Management Team:

Gavin Upiter – Chairman

Gavin has over 25 years of experience leading companies in the pharmaceutical sector. Engineering qualified, prior to founding Generic Health, a leading generic pharmaceutical company which was sold to Lupin Pharmaceuticals, (NSE: LUPIN), Gavin started his executive career at Bristol Myers Squibb. He was Australian CEO of Amneal Pharmaceuticals (NYSE: AMRX) and Executive Director of Slade Health, Australia’s leading hospital pharmacy chain. Gavin founded Directo, Australia’s first online pharmaceutical B2B marketplace for pharmacies and suppliers.

Dr. Zena Burgess, PhD. FAICD,FAPS – Non-Executive Director

Zena has a strong interest in the future of health care. She serves as the Chief Executive Officer of the Australian Psychologists Society and formerly as Chief Executive of the Royal Australian College of General Practitioners. She is a member of the international advisory board of Connext2MyDoctor and the telehealth influencers alliance. She is also a director of the Australian Patients Association and Chair of the board subcommittee on governance and risk of the Victorian Farmers Federation. Zena has substantial experience serving on boards of government entities. She holds a PhD in psychology from the Australian Catholic University and a Master of Business Administration from Monash University and a Master of Education from La Trobe University. She has a wealth of experience in health changes and strategic advocacy to governments.

Justin Hanka – Co-Founder & Director

Justin Hanka is in investment banking and financing of mergers and acquisitions and capital markets transactions. He is Non-Executive Director of EonX (CSE:EONX), a financial technology company, Non-Executive Director of Goldcar, (a Europcar Company listed on the Euronext in France), Non-Executive Director of The Digital Tribes Company, an IT digital transformation company headquartered in Sweden. He is an experienced executive having served as Chief Operating Officer for iSelect (ASX: ISU) and having sold Helpmechoose as its CEO to Mortgage Choice (ASX:MOC). Justin’s expertise spans the pharmaceutical and health sector including pharmaceuticals, pharma-technologies, fin-techs, digital transformation and technology, influencer marketing, health and wellness, entertainment and ecommerce.

Colin Keating – Chief Executive Officer

Colin is an experienced CEO and Managing Director having led publicly listed Hogg Robinson Group Australia (LSE) and BuyMyPlace (ASX), both large private technology led organisations and has also held senior global leadership positions with the likes of American Express. With over 25 years experience in both established and scale up businesses, Colin possesses a demonstrable track record in driving growth, shaping organisational culture and delivering shareholder value. His experience is broad and varied having worked across multiple industries including Financial Services & Payments, Corporate Travel, Property Tech, Health Tech, Data Management and Wealth Management. Colin also has deep experience working in, and advising, organisations on strategic initiatives such as capital raising, M&A activities, IPO’s and exit strategies. Having worked in the United Kingdom, Hong Kong and the US, Colin’s global experience will be of enormous benefit to Mind Therapeutics as the business grows both domestically and across international markets.

Scientific Team:

Dr Suresh Muthukumaraswamy, PhD BSc Hons – Lead Scientist

Suresh is an Associate Professor of Psychopharmacology in the Faculty of Medical and Health Sciences at the University of Auckland. Suresh’s main research interests are in understanding how therapies alter brain activity and in developing methodologies to measure these changes in both healthy individuals and patient groups – particularly those with depression. His previous studies have involved a range of compounds including hallucinogens (ketamine, LSD, psilocybin), anesthetics (propofol, dexmedetomidine), anti-epileptics (vigabatrin, perampanel, tiagabine) and GABA-enhancers (zolpidem, gaboxadol).

He is currently leading clinical trials investigating LSD microdosing and other new antidepressant therapies. Suresh has published over 100 scientific papers in the field of psychopharmacology and neuroimaging which have been cited over 6500 times. Suresh has received several awards including a prestigious Rutherford Discovery Fellowship and several grants from the Health Research Council of New Zealand.

Dr Nicholas Hoeh, MD.Am.BD.Cert Psych, – Psychiatrist

Nick is a consultant psychiatrist working part time at the Auckland District Health Board and in private practice. Additionally, he is a professional teaching fellow in Psychological Medicine at the University of Auckland. He obtained his medical degree at the University of Medicine and Dentistry in New Jersey and completed his internship, psychiatry residency, and old age psychiatry fellowship at the University of Pennsylvania in Philadelphia. Nick’s current research interests include the clinical use of repetitive transcranial magnetic stimulation and psychedelics for treatment resistant depression.

Dr Rachael Sumner, PhD.Pharma. MSc Hons. BA. Hons. Psych – Clinical Research Associate

Dr Sumner is a leading researcher in the field of psychedelics and has been involved in numerous research studies in her work at the University of Auckland. Notable studies include the use of Ketamine in the treatment of depression and the overarching aim and application of Dr Sumner’s research is to validate non-invasive electrophysiological assays of brain function in neurological and psychiatric health and disease.

Dr Frederick Sundram, PhD. MSc. MA. FRCPsych(UK). MB BCh. BAO; B.MedSc. – Psychiatry & Technology Consultant

Frederick is an Associate Professor at the Department of Psychological Medicine at the University of Auckland and a Consultant Liaison Psychiatrist at North Shore Hospital. Previously he was research fellow at the Department of Forensic and Neurodevelopmental Science at the Institute of Psychiatry, King’s College London and the Royal College of Surgeons in Ireland where he completed his PhD in Neuroimaging. Frederick also completed a Masters in Healthcare Management at the Institute of Public Administration, Dublin and a Masters in Healthcare Informatics. His research interests include depression, neuroimaging, self-harm/suicide, medical education, overlap between medicine and psychiatry, medically unexplained physical symptoms and healthcare informatics.

Dr Partha Roop, PhD. M.Tech. BEng. – AI & Machine Learning

Partha’s research interests are in Digital Health, Formal Methods for Safety-Critical applications of AI and Machine Learning, and Real-Time Systems. Partha is working with colleagues from the Medical School and the Auckland Bioengineering Institute (ABI) on new techniques developed by his group known as organ on a chip. He is also interested in heart rate variability and Biofeedback.

Transaction Structure

In connection with the acquisition, the Company proposes to acquire all of the outstanding share capital of 1286409 B.C. Ltd. (the “Parent”), of which MindBio Therapeutics is a wholly-owned subsidiary. In consideration for the completion of the transaction, the Company is required to issue 22,095,180 common shares to the existing shareholders of the Parent.

The Company is at arm’s length from the Parent, MindBio Therapeutics and its shareholders. The transaction neither constitutes a fundamental change nor a change of business for the Company, nor has it expected to result in a change of control of the Company within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. Completion of the acquisition remains subject to the satisfaction of customary closing conditions. Following completion of the acquisition, MindBio Therapeutics will form part of the Company’s existing portfolio of investments in the health care sector. MindBio Therapeutics’s existing board and directors will continue to retain responsibility for overseeing day-to-day operations, based upon an agreed budget.

Blackhawk would like to encourage all investors and interested parties to take a look at a MindBio Therapeutics’ recently uploaded video here: https://www.linkedin.com/feed/update/urn:li:activity:6830643767087910912 as well as their corporate website which can be found here: https://mindbiotherapeutics.com/

Justin Hanka of MindBio Therapeutics will also be presenting at the Psychedelic Capital Investment Conference Today, Tuesday, August 31st 2021 at 2:55pm EST. Everyone is highly encouraged to register for the conference here: https://microdose.buzz/shop/events/psychedelic-capital/psychedelic-capital-aug-2021/

About Blackhawk Growth

Blackhawk is an investment holding looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food and NuWave Foods. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Posted on

MINDCURE Announces Financial Results for Fiscal 2021

MINDCURE Announces Financial Results for Fiscal 2021

VANCOUVER, BC, August 31, 2021 – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research in psychedelics, today announced its financial results for the three and twelve months ended May 31, 2021. All amounts are stated in Canadian dollars unless otherwise indicated.  

Business Highlights

  • Commenced the development of iSTRYM, the Company’s digital therapeutics tool, a first-of-its-kind software application that will optimize the healing journey for both patients and clinicians — before, during, and after therapy sessions;
  • Submitted a provisional patent application with the United States Patent and Trademark Office to cover various aspects of iSTRYM;
  • Commenced the first stage of manufacturing synthetic ibogaine;
  • Subsequent to year end, completed full chemical synthesis of ibogaine and filed two provisional patent applications in association with synthesis routes;
  • Made several additions to its senior management team and board of directors and retained a number of advisors;
  • Completed a strategic equity investment in ATMA Journey Centers Inc.; and,
  • Subsequent to year end, completed a strategic equity investment in Awakn Life Sciences Inc.

“MINDCURE’s first full year of operations was full of outstanding accomplishments and highlighted by the successful completion of several milestones,” said Kelsey Ramsden, President & CEO of MINDCURE. “The strategy and infrastructure we have put in place over the past year positions the company well to continue the development and release of our digital therapeutics platform, iSTRYM, and to continue our research for psychedelics. The company’s achievements could not have happened without the hard work and commitment of the entire MINDCURE team, our Board of Directors and our advisors. I would like to especially thank our investors for seeing and supporting the vision and execution at MINDCURE.”

Financial Highlights

  • Raised net proceeds of $27.2 million through the issuances of common shares and the exercise of warrants and options;
  • Cash and cash equivalents totalled $18.3 million as of May 31, 2021; and
  • Net loss was $10.2 million for the year ended May 31, 2021, comprised of non-cash operating expenses of $2.0 million and cash operating expenses of $8.1 million.

A copy of the Company’s audited consolidated financial statements for the year ended May 31, 2021, and the related management’s discussion and analysis are available under the Company’s profile on SEDAR at www.sedar.com.

About Mind Cure Health Inc.

MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors

Kelsey Ramsden, President & CEO

Phone: 1-888-593-8995

Forward-Looking Information

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that iSTRYM will be developed, optimized and operate as contemplated within the psychedelics industry; that the Company will be effective in obtaining the patents applied for synthesizing ibogaine, or synthesizing ibogaine, or developing synthesized ibogaine for research, medical or commercial use; that MINDCURE will advance wellness worldwide; that iSTRYM will be brought to commercial deployment in the near term or otherwise or that it will reduce symptoms, improve quality of life, or support transformation and healing, or that the deployment may not occur at the scale or within the time frame contemplated.

Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.  

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

For further information:

MINDCURE Investor Relations

investors@mindcure.com

1-888-593-8995

Posted on

Optimi Health Appoints New Chief Executive Officer

Optimi Health Appoints New Chief Executive Officer

VANCOUVER, British Columbia, August 31, 2021 — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that William (Bill) J. Ciprick has been appointed as the Company’s Chief Executive Officer, effective as of September 7, 2021.

Mr. Ciprick brings over 30 years of global experience across a wide array of industries in multifunctional organizations ranging from Fortune 500 corporations to small and medium-sized Canadian businesses. Throughout his career, he has developed a broad set of skills with a focus on growth strategies, sales, marketing, organizational development, mergers, acquisitions, and turnarounds. He recently served as Senior Vice President at BDC Advisory Services. In this role he was responsible for leading BDC’s High-Impact Firm team, as well as the successful execution of related programs. Previously, Mr. Ciprick was President and Executive Consultant with ATG Consulting, focusing on conducting organizational assessments and redesigns, and on developing and supporting the development and implementation of strategic plans. In one mandate, he stepped in as Acting Executive Vice President of Operations for a mid-sized firm specializing in roofing and building envelope products, driving a significant increase in profitability and overseeing the disposal of assets to help recapitalize the company. Prior to ATG, Mr. Ciprick was Vice President of Strategy and Business Development for SMART Technologies, where he developed and deployed the first strategic planning process and delivered the largest acquisition in the company’s history. He also spent more than 16 years at Procter & Gamble, holding management positions including Senior Vice President, Sales for the P&G North America Beauty division. Mr. Ciprick holds a Bachelor of Arts degree in Economics from the University of British Columbia.

In agreeing to join Optimi as its Chief Executive Officer, Bill Ciprick commented, “ I am delighted and excited by the Optimi opportunity. The Company is rapidly moving beyond their initial start-up and build-out into commercialization of functional mushroom products concurrent with their advanced research and studies aimed at the increasingly important mental health & wellness field. The commitment the entire Optimi team brings to achieving the highest industry standards for the scientific investigation and development of an all-natural mushroom product platform is in my opinion second-to-none, and represents an attractive business proposition. I have found the business to be structurally sound and ready to grow – which is a testament to their initial start-up approach. I look forward to helping build Optimi into a sector-leading commercial enterprise.”

Outgoing CEO Mike Stier advised, “The work we undertook since inception, and ultimately with our public listing, has provided the initial market visibility and financing to enable healthy progress and created a detailed roadmap for future growth. Now is the time for a steady hand focussed on commercialization and product development. Bill has the leadership experience and background we believe will guide the Company into the next phase of development. With leaders like Bill participating in the sector, I look forward to a bright future for Optimi Health and the industry as a whole.”

Mr. Ciprick is replacing Mike Stier as Chief Executive Officer of the Company. Optimi would like to thank Mr. Stier for his numerous contributions as Chief Executive Officer and is pleased to announce that he will remain as a director of the company.

In connection with his appointment, the Company has granted Mr. Ciprick an aggregate of 73,077 common shares in the capital of the Company and issued 1,000,000 incentive stock options to Mr. Ciprick. The options were granted under the Company’s Equity Incentive Plan and each stock option entitles the holder to acquire one common share in the capital of the Company at an exercise price of $1.50 per share until August 31, 2026. One quarter of the options will vest immediately and the remaining options will vest in three equal installments on the first, second and third anniversary of the date hereof.

ABOUT OPTIMI (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN)
Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.

FOR FURTHER INFORMATION CONTACT:
Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (778) 930-1321
Web: https://optimihealth.ca/

FORWARD‐LOOKING STATEMENTS
This news release contains forward-looking statements, including regarding the development of the Company’s business and management team. These forward-looking statements are provided as of the date of this news release, and reflect predictions, expectations or beliefs regarding future events based information currently available to the Company. In making the forward-looking statements included in this news release, the Company has applied several material assumptions, including that general economic and business conditions will not change in a materially adverse manner. Although management considers these assumptions to be reasonable based on information available to them, they may prove to be incorrect. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions on which they are based do not reflect future experience. We caution readers not to place undue reliance on these forward-looking statements as a number of important factors could cause the actual outcomes to differ materially from the expectations expressed in them. These risk factors may be generally stated as the risk that the assumptions and estimates expressed above do not occur, but specifically include, without limitation, risks relating to: general market conditions and the additional risks described in the Final Shelf Prospectus and the Company’s Annual Information Form, and other disclosure documents filed by the Company on SEDAR. The foregoing list of factors that may affect future results is not exhaustive. When relying on our forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. The Company does not undertake to update any forward-looking statement, whether written or oral, that may be made from time to time by the Company or on behalf of the Company, except as required by law.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Posted on

Red Light Closes Acquisition of Mera Life Sciences and Files Quarterly Financial Statements

Red Light Closes Acquisition of Mera Life Sciences and Files Quarterly Financial Statements

Toronto, Ontario–(Newsfile Corp. – August 31, 2021) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company”), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles, is pleased to announce that its financial results for the quarter ended June 30, 2021 (“Q1FY22”) have been filed on SEDAR. Separately, the Company has closed its previously announced acquisition of Mera Life Sciences (“Mera”).

Financial Statements

The Company is pleased to announce that its annual financial statements for the quarter ended June 30, 2021 are now available on SEDAR and highlights key data points below:

– Q1 FY22 revenue grew 521% over Q4 FY2, to $595,137

– Cash balance remains healthy, in excess of $29 million

– Company remains committed to identifying and executing M&A transactions within psychedelics and recreational THC markets

“I’m so proud of our team for another great quarter. This is the second quarter in a row we have grown revenues by over 500%, and growing our revenues on a quarterly basis remains a core focus of our business in becoming a revenue focused Psychedelic Company,” said Todd Shapiro, CEO and Director of Red Light Holland. “As well, our team remains razor focused on identifying and executing additional M&A transactions in both the psychedelics and recreational THC sectors, and we hope to bring additional deals to the market over the coming months with counterparties that exhibit material revenue capabilities and cautious spending habits.”

Mera Life Sciences

Shapiro added: “Separately, we have also completed the acquisition of Mera and its coveted psychedelic licenses in St. Vincent and the Grenadines. We have renamed Mera to Scarlette Lillie Science and Innovation, which allows for us to carefully pursue financially disciplined high quality psychedelic product research and development, open up treatment clinics, cultivate, extract and process, and export not just Psilocybin, but other compounds such as Ayahuasca, MDMA, DMT, Peyote, Ketamine and many other natural based plants. Red Light Holland can now explore the inner molecular worlds of multiple plant species, including a variety of psychedelics potentially putting us in a position to discover novel clinical applications for a variety of natural psychedelics. We hope to be on the frontier of natural plant based drug discovery while being in control of the inner workings including staffing, budgeting and a synergistic company culture.”

“Working through the Mera acquisition with the various stakeholders involved has been a really fantastic experience,” said William Lay, EVP and Chief Strategy Officer of Red Light Holland. “I’m really excited for Red Light to take advantage of such a comprehensive applied science landscape to further its initiatives within the Scarlette Lillie Sciences and Innovation division, and to continue pursuing attractive M&A opportunities.”

Hon. Minister Saboto Ceasar, Minister of Agriculture, Forestry, Fisheries, Rural Transformation Industry and Labor of St. Vincent and the Grenadines added: “We welcome Red Light Holland and Scarlette Lillie Sciences and Innovation as one of the Pioneer Licensees in St. Vincent and the Grenadines’ modern medicinal wellness industry. Our mantra is that this industry ‘begins and ends with science’. This important event demonstrates that our legal framework and wide range of protocols will make St Vincent and the Grenadines an enviable business and research destination for serious scientists and psychedelics companies. Red Light Holland is a world-class, professional organization that patiently worked through all details required to ensure a successful and profitable venture. Their CEO Todd Shapiro has invested and established roots here in our country that will flourish into a special partnership. We are excited to work with the entire team as they continue their march forward.”

The Acquisition was completed pursuant to the terms of the definitive agreement (the “Acquisition Agreement”) dated July 29, 2021, pursuant to which Red Light Holland acquired 100% of the issued and outstanding shares of Mera for $2,450,000. The consideration will be comprised of up to 7,000,000 common shares of the Company (the “Red Light Shares”), with each Red Light Share priced at $0.35, representing a 35% premium to the closing price of the Red Light Shares on the Canadian Securities Exchange immediately prior to the closing of the Acquisition. Upon closing of the transaction, the Company issued 700,000 Red Light Shares to the vendor of Mera.

The remaining 6,300,000 Red Light Shares will be released to the vendors based on the achievement of several milestones, which include: the importation of 15,000 grams of iMicrodose truffles to St. Vincent and the Grenadines (“SVG”), governmental authority to rename Mera to Scarlette Lillie Sciences and Innovation, the successful prescription and sale of iMicrodose truffles to at least five patients in SVG or the successful administration of iMicrodose truffles to at least five participants in a scientific study or trial in SVG, the extraction and testing of the iMicrodose truffles, the successful export of iMicrodose truffles from SVG to another jurisdiction, and the final implementation of SVG’s regulatory framework for the psychedelics industry.

Mera currently holds a Medicinal Industry Development License (the “License“) issued by the SVG Bureau of Standards, which permits the research, cultivation, production, development and extraction, import and export, clinical treatment facilities, and prescribed patient access in specifically licensed clinical treatment facilities. The License applies to the following compounds: Tumeric, Aloe Vera, Papaya, Arrowroot, Soursop, Coconut, Ginger, Moringa, Ayahuasca, Mushroom, Iboga, Sassafras, Peyote, Psilocybin, Ibogaine, Dimethyltryptamine (DMT), Mescaline, Ketamine, 3-4 Methylenedioxy – Methamphetamine (MDMA), Lysergic Acid Diethylamide (LSD), 5-Methoxy-N,N-Dimethyltrypotomine (5-MeO-DMT). The Company has worked closely with the SVG government over the last 6 months to assist in the development of the final regulatory framework which will govern the Company’s expected activities in SVG, and has been informed by the SVG government that it expects these regulations, which are in substantially final form, to be signed into law in the near future.

Mera has been renamed Scarlette Lillie Science and Innovation (“SLSI”) and will serve as a key growth driver with respect to its ability to engage in various research and applied science applications.

About Red Light Holland

Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles.

For additional information on the Company:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-204-7129
Email: todd@redlighttruffles.com
Website: https://redlighttruffles.com/

Forward-Looking Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control.

Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward- looking statements contained herein include but are not limited to: identify and executing M&A transactions within psychedelics and recreational THC markets; the completion of the conditions with respect to the 6,300,000 Red Light Holland Shares; the signing of the regulations developed in conjunction with the SVG government into law; and the ability of SLSI to drive growth.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company’s ability to continue as a going concern; the continued commercial viability and growth in popularity of functional mushrooms and/or magic truffles; continued approval of the Company’s activities by the relevant governmental and/or regulatory authorities; and the ability of the Company to fulfil the listing requirements of the CSE.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the risks associated with the psychedelics industry in general such as operational risks in growing, competition, incorrect assessment of the value and potential benefits of various transactions; the inability of the Company to identify and execute M&A transactions within psychedelics and recreational THC markets; the non-completion of the conditions with respect to the 6,300,000 Red Light Holland Shares; the refusal of the SVG government to sign the regulations developed with the Company into law the inability of SLSI to drive growth; the diversion of management time on transaction-related issues; expectations regarding future investment, growth and expansion of the operations of the businesses; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets; risks related to infectious diseases, including the impacts of the COVID-19 pandemic; legal and regulatory risks inherent in the cannabis and magic psychedelics industries, including the global regulatory landscape and enforcement related to cannabis and psychedelics, political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the cannabis and psychedelics industries; and such other risks contained in the public filings of the Company filed with Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. Red Light Holland disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

Distinguished Psychedelic Researcher, Professor of Psychiatry and Neuroscience, Rachel Yehuda, PhD, Joins Wesana Health Scientific Advisory Board

Distinguished Psychedelic Researcher, Professor of Psychiatry and Neuroscience, Rachel Yehuda, PhD, Joins Wesana Health Scientific Advisory Board

TORONTO and CHICAGO, Aug. 31, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), an emerging data driven life sciences company focused on developing innovative approaches for better understanding, protecting and improving neurological health and performance, including through the advancement of psychedelic medicines, today announced the addition of distinguished psychedelics researcher and professor, Rachel Yehuda, PhD, to its Scientific Advisory Board. In this role, Dr. Yehuda will provide strategic guidance and direction to Wesana’s scientific research efforts related to psychedelic-assisted psychotherapy and traumatic brain injury (TBI).

Dr. Yehuda has been at the vanguard of trauma research and treatment for over three decades. She is a Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai, and Director of The Center for Psychedelic Psychotherapy and Trauma Research at Mount Sinai, which will further research MDMA-assisted psychotherapy and other psychedelic-assisted psychotherapies with compounds such as psilocybin to treat trauma. She is also Director of the Traumatic Stress Studies Division at Icahn Mount Sinai which includes the PTSD clinical research program.

On her appointment, Dr. Yehuda said, “The research of novel treatment approaches for trauma and other mental health conditions through psychedelics may fundamentally change our understanding of these conditions, as well as the current treatment landscape. For that to happen though, the research must be held to the highest possible standard. As part of Wesana’s Scientific Advisory Board, I look forward to offering my guidance and experience on this front as they explore ways to improve neurological health.”

“Dr. Yehuda has led federally-funded research programs that have revolutionized the current understanding and treatment of trauma and has been a driving force in the current FDA trials to study MDMA as a psychedelic therapy. Her knowledge, understanding, and guidance will be invaluable as we accelerate our efforts to research and develop treatments for TBI and other debilitating neurological ailments,” said Daniel Carcillo, co-founder and CEO of Wesana Health.

“Wesana is committed to building a team of the very best advisors, thinkers and leaders to ensure that we are operating at the highest possible level in scientific and psychedelic research and development. As a global expert in her field, Dr. Yehuda will play an important leadership role as we continue to execute on our strategic research goals,” said Chad Bronstein, co-founder and Executive Chairman.

Dr. Yehuda has authored more than 450 published papers, chapters, and books in the field of traumatic stress and the neurobiology of PTSD. She received her PhD in Psychology and Neurochemistry and her MS in Biological Psychology from the University of Massachusetts at Amherst and completed her postdoctoral training in Biological Psychiatry in the Psychiatry Department at Yale Medical School.

Dr. Yehuda receives financial compensation as a scientific advisor for Wesana Health.

About Wesana
Wesana is an emerging life sciences company championing the development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI). Through extensive clinical research and academic partnerships, Wesana is developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological and mental health ailments caused by trauma.

Learn more at www.wesanahealth.com

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws with respect to the Company, including, but not limited to, information concerning the anticipated timing for receipt of results from the anxiety and depression study described above and the anticipated timing for commencement and conclusion of the Pivotal Study described above. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “will”, “projects”, or “believes” or variations (including negative variations) of such words and phrases, or statements that certain actions, events, results or conditions “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Except for statements of historical fact, information contained herein constitutes forward-looking information.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management at the date the statements are made including among other things assumptions about: research and development costs remaining consistent with budgets; favorable operating conditions; political and regulatory stability; obtaining and maintaining all required licenses and permits; receipt of governmental approvals and permits; sustained labor stability; the ability of the Company to be successful in its research and development initiatives; and the availability of third party service providers and other inputs for the Company’s operations. While the Company considers these assumptions to be reasonable, the assumptions are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual performance, achievements, actions, events, results or conditions to be materially different from those projected in the forward-looking information. Many assumptions are based on factors and events that are not within the control of the Company and there is no assurance they will prove to be correct.

Furthermore, such forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, financial position, performance or achievements of the Company to be materially different from any future plans, intentions, activities, results, financial position, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others: research and development of drugs targeting the central nervous system being particularly difficult; delivering data from ongoing pre-clinical and clinical studies; competition from other biotechnology and pharmaceutical companies; reliance on third parties to plan, conduct and monitor preclinical studies and clinical trials; negative results from pre-clinical and clinical trials or studies of others; unfavorable publicity or consumer perception; not achieving publicly announced milestones; reliance on the capabilities and experience of key executives and scientists; disruptions due to acquisitions or collaborations; risk of product liability claims; COVID-19; litigation; conflicts of interest; limited operating history; exposure to the fluctuation of foreign exchange rates; ability to protect intellectual property; changes in patent law; requirements to share intellectual property with service providers; general economic, market and business conditions, other risks factors including those found in the Company’s Listing Statement dated May 6, 2021 filed on SEDAR at www.sedar.com and discussed in the Company’s other public filings available on SEDAR. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information will prove to be accurate as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. Forward-looking information is provided and made as of the date of this news release and the Company does not undertake any obligation to revise or update any forward-looking information other than as required by applicable law.

For more information, please contact:

Media Contact:
Nick Opich / Annie Graf
KCSA Strategic Communications
Email: Wesana@kcsa.com
Phone: 212-896-1206 / 786-390-2644

On behalf of the Board of Directors:
Daniel Carcillo, Chief Executive Officer
Phone: (773) 236-7972

Primary Logo

Source: Wesana Health

Released August 31, 2021